Ensysce Biosciences completes clinical portion of PF614-MPAR-101 Part A trial

Ensysce Biosciences announced that it has completed the clinical portion of study PF614-MPAR-101 Part A, entitled ‘Single-Dose Study to Evaluate the Pharmacokinetics of oxycodone and PF614, when PF614 Solution is Co-Administered with Nafamostat, as an Immediate-Release Solution and/or Extended-Release Capsule Formulations in Healthy Subjects’, being conducted by Dr. Maria Bermudez MD, at Quotient Sciences, Miami Florida. MPAR is designed to prevent drug overdose by inhibiting the activation and release of opioid when more than prescribed doses are taken. PF614 is a TAAP prodrug of oxycodone designed to reduce abuse of this opioid pain medication. TAAP chemical modification inactivates the active ingredient in Ensysce’s products until they are swallowed and exposed to a digestive enzyme, trypsin. PF614 requires exposure to trypsin, which safely turns ‘on’ the release of oxycodone. The PF614-MPAR has additional protection of an added trypsin inhibitor, nafamostat, to turn ‘off’ the release of oxycodone in an overdose situation. The MPAR combination technology of a TAAP prodrug and a trypsin inhibitor is the first platform that the Company expects may prevent all four common methods of opioid abuse – chewing, inhaling, injecting and oral overdose.